679 Pharmacokinetics of direct oral anticoagulants in patient with atrial fibrillation and extreme obesity
Abstract Aims Direct oral anticoagulants (DOACs) are recommended in preference to vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation (AF) eligible for oral anticoagulation therapy; however, data and clinical experiences supporting the use of DOACs in patients wit...
Saved in:
Published in | European heart journal supplements Vol. 23; no. Supplement_G |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
08.12.2021
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Aims
Direct oral anticoagulants (DOACs) are recommended in preference to vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation (AF) eligible for oral anticoagulation therapy; however, data and clinical experiences supporting the use of DOACs in patients with a body mass index ≥40 kg/m2 or weight >120 kg remain limited. The aim of this study was to evaluate the pharmacokinetic properties of DOACs in patients with AF and extreme obesity.
Methods and results
We enrolled all consecutive patients with AF and extreme obesity undergoing treatment with DOACs followed up at Monaldi Hospital, Naples, Italy. To determine peak plasma and trough levels of DOACs, plasma samples were collected at 2nd, 4th, 6th, and 12th hours from the last dose intake in patients receiving apixaban and dabigatran and at the 2nd, 4th, 6th, and 24th hours in those receiving edoxaban and rivaroxaban. The DOACs’ peak and trough plasma levels obtained from our study population were compared with those sourced from pharmacokinetic studies among patients without obesity, defined as a normal reference range in the literature. If at least 1 peak or trough plasma level was found below or above the normal reference ranges, the patients were classified as having out-of-range DOAC plasma levels. Study population was then divided into in-range and out-of-range groups. Baseline characteristics, including DOAC treatment, were compared between the two groups. Univariate and multivariate logistic regression analyses were performed to identify baseline variables associated with DOACs’ plasma concentration out of the expected range. A total of 58 patients [mean (SD) age, 70.93 (8.73) years; 40% female] with extreme obesity [mean (SD) body mass index, 44.43 (3.54) kg/m2] and AF while undergoing DOAC treatment was included in the present study. In nine patients (15.5%), the DOAC plasma concentrations were out of the expected ranges (out-of-range group);, indicating a greater likelihood of edoxaban 30 mg treatment (33% vs. 2%; P < 0.01) and inappropriate DOAC underdosing (56% vs. 4%; P < 0.005) compared with the in-range group. According to the multivariate logistic analysis (P = 0.0011), the inappropriate DOAC underdosing (hazard ratio = 29.37; P = 0.0002) was an independent predictor of DOAC plasma levels out of the expected ranges.
Conclusions
Patients with extreme obesity and AF who were receiving DOAC therapy had DOAC plasma concentrations in the expected range. The inappropriate DOAC underdosing seems to be the only independent clinical factor associated with a plasma concentration of the drug out of the expected range. |
---|---|
AbstractList | Abstract
Aims
Direct oral anticoagulants (DOACs) are recommended in preference to vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation (AF) eligible for oral anticoagulation therapy; however, data and clinical experiences supporting the use of DOACs in patients with a body mass index ≥40 kg/m2 or weight >120 kg remain limited. The aim of this study was to evaluate the pharmacokinetic properties of DOACs in patients with AF and extreme obesity.
Methods and results
We enrolled all consecutive patients with AF and extreme obesity undergoing treatment with DOACs followed up at Monaldi Hospital, Naples, Italy. To determine peak plasma and trough levels of DOACs, plasma samples were collected at 2nd, 4th, 6th, and 12th hours from the last dose intake in patients receiving apixaban and dabigatran and at the 2nd, 4th, 6th, and 24th hours in those receiving edoxaban and rivaroxaban. The DOACs’ peak and trough plasma levels obtained from our study population were compared with those sourced from pharmacokinetic studies among patients without obesity, defined as a normal reference range in the literature. If at least 1 peak or trough plasma level was found below or above the normal reference ranges, the patients were classified as having out-of-range DOAC plasma levels. Study population was then divided into in-range and out-of-range groups. Baseline characteristics, including DOAC treatment, were compared between the two groups. Univariate and multivariate logistic regression analyses were performed to identify baseline variables associated with DOACs’ plasma concentration out of the expected range. A total of 58 patients [mean (SD) age, 70.93 (8.73) years; 40% female] with extreme obesity [mean (SD) body mass index, 44.43 (3.54) kg/m2] and AF while undergoing DOAC treatment was included in the present study. In nine patients (15.5%), the DOAC plasma concentrations were out of the expected ranges (out-of-range group);, indicating a greater likelihood of edoxaban 30 mg treatment (33% vs. 2%; P < 0.01) and inappropriate DOAC underdosing (56% vs. 4%; P < 0.005) compared with the in-range group. According to the multivariate logistic analysis (P = 0.0011), the inappropriate DOAC underdosing (hazard ratio = 29.37; P = 0.0002) was an independent predictor of DOAC plasma levels out of the expected ranges.
Conclusions
Patients with extreme obesity and AF who were receiving DOAC therapy had DOAC plasma concentrations in the expected range. The inappropriate DOAC underdosing seems to be the only independent clinical factor associated with a plasma concentration of the drug out of the expected range. |
Author | Natale, Francesco Parente, Erika D’Aquino, Marco Malvezzi Caracciolo Golino, Paolo Fabiani, Dario Russo, Vincenzo Pezzullo, Enrica Uccello, Ambra Scognamiglio, Gabriella Giannetti, Laura |
Author_xml | – sequence: 1 givenname: Laura surname: Giannetti fullname: Giannetti, Laura organization: Dipartimento di Scienze Mediche Traslazionali. Università degli Studi della Campania Luigi Vanvitelli, Ospedale Monaldi, Napoli, Italy – sequence: 2 givenname: Enrica surname: Pezzullo fullname: Pezzullo, Enrica organization: Dipartimento di Scienze Mediche Traslazionali. Università degli Studi della Campania Luigi Vanvitelli, Ospedale Monaldi, Napoli, Italy – sequence: 3 givenname: Marco Malvezzi Caracciolo surname: D’Aquino fullname: D’Aquino, Marco Malvezzi Caracciolo organization: Dipartimento di Scienze Mediche Traslazionali. Università degli Studi della Campania Luigi Vanvitelli, Ospedale Monaldi, Napoli, Italy – sequence: 4 givenname: Gabriella surname: Scognamiglio fullname: Scognamiglio, Gabriella organization: Dipartimento di Scienze Mediche Traslazionali. Università degli Studi della Campania Luigi Vanvitelli, Ospedale Monaldi, Napoli, Italy – sequence: 5 givenname: Erika surname: Parente fullname: Parente, Erika organization: Dipartimento di Scienze Mediche Traslazionali. Università degli Studi della Campania Luigi Vanvitelli, Ospedale Monaldi, Napoli, Italy – sequence: 6 givenname: Ambra surname: Uccello fullname: Uccello, Ambra organization: Dipartimento di Scienze Mediche Traslazionali. Università degli Studi della Campania Luigi Vanvitelli, Ospedale Monaldi, Napoli, Italy – sequence: 7 givenname: Dario surname: Fabiani fullname: Fabiani, Dario organization: Dipartimento di Scienze Mediche Traslazionali. Università degli Studi della Campania Luigi Vanvitelli, Ospedale Monaldi, Napoli, Italy – sequence: 8 givenname: Francesco surname: Natale fullname: Natale, Francesco organization: Dipartimento di Scienze Mediche Traslazionali. Università degli Studi della Campania Luigi Vanvitelli, Ospedale Monaldi, Napoli, Italy – sequence: 9 givenname: Paolo surname: Golino fullname: Golino, Paolo organization: Dipartimento di Scienze Mediche Traslazionali. Università degli Studi della Campania Luigi Vanvitelli, Ospedale Monaldi, Napoli, Italy – sequence: 10 givenname: Vincenzo surname: Russo fullname: Russo, Vincenzo organization: Dipartimento di Scienze Mediche Traslazionali. Università degli Studi della Campania Luigi Vanvitelli, Ospedale Monaldi, Napoli, Italy |
BookMark | eNo9kMtKAzEUhoNUsK0-gpAXmDaXyUyzlOINCrrowt1wJnNiU6dJSVK0O8E39Ukcsbj6P_5zWXwTMvLBIyHXnM0403KOh7hBiHk7TwdouahnTKgzMuZKlYVYcDX6ZcGKulIvF2SS0pYxIRclG5O-qvX359fzBuIOTHhzHrMziQZLOxfRZBoi9BT80AZ4PfQDJeo83UN26DN9d3lDIUc3bFnXRtf3wyT44aSj-JEj7pCGFpPLx0tybqFPeHXKKVnf3a6XD8Xq6f5xebMqjJaqgHYhtaxl1VWl6RDQal0Bt62WYDXIsrMMQLGOc2mlsaqUwKC1QppaWAFyStTfWxNDShFts49uB_HYcNb8Gmv-jTUnY81gTP4Anslp4A |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1093/eurheartj/suab127.025 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1554-2815 |
ExternalDocumentID | 10_1093_eurheartj_suab127_025 |
GroupedDBID | .2P .ZR 0R~ 18M 2WC 4.4 48X 53G 5GY 5RE 5VS 5WD AABZA AACZT AAJKP AAMVS AAOGV AAPQZ AAPXW AARHZ AASNB AAUAY AAVAP AAYXX ABEUO ABIXL ABJNI ABKDP ABNHQ ABNKS ABPTD ABQLI ABQNK ABWST ABXVV ABZBJ ACGFS ACUFI ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGQXC AGSYK AGUTN AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT ATGXG AXUDD BAWUL BAYMD BCGUY BCRHZ BEYMZ BHONS BTRTY BVRKM CDBKE CITATION CS3 DAKXR DIK DILTD D~K E3Z EBS EE~ ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HZ~ J21 KOP KQ8 KSI KSN MHKGH NOMLY NOYVH O9- OAUYM OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM Q1. RD5 RHF ROL ROX RUSNO RW1 RXO TEORI TJX TR2 W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 |
ID | FETCH-LOGICAL-c935-ab8393736d64cdeaef996a1fb93af9a34df0aa50d113f3cf543a0abf23c72f2a3 |
ISSN | 1520-765X |
IngestDate | Fri Aug 23 01:11:50 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_G |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c935-ab8393736d64cdeaef996a1fb93af9a34df0aa50d113f3cf543a0abf23c72f2a3 |
OpenAccessLink | https://academic.oup.com/eurheartjsupp/article-pdf/23/Supplement_G/suab127.025/41683363/suab127.025.pdf |
ParticipantIDs | crossref_primary_10_1093_eurheartj_suab127_025 |
PublicationCentury | 2000 |
PublicationDate | 2021-12-08 |
PublicationDateYYYYMMDD | 2021-12-08 |
PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-08 day: 08 |
PublicationDecade | 2020 |
PublicationTitle | European heart journal supplements |
PublicationYear | 2021 |
SSID | ssj0023840 |
Score | 2.284763 |
Snippet | Abstract
Aims
Direct oral anticoagulants (DOACs) are recommended in preference to vitamin K antagonists (VKAs) for stroke prevention in patients with atrial... |
SourceID | crossref |
SourceType | Aggregation Database |
Title | 679 Pharmacokinetics of direct oral anticoagulants in patient with atrial fibrillation and extreme obesity |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaWIiEuiKegPOQDtyrbxM7Lx4qWLaAiJBZpb9HEsauUJaHLLoc9IfEP-Qn8EsaPZLPVClEuVmTJVuz5ZI9n5psh5GUeVkwwLYOkjKvAOIoCEKkM0koyzVQYVdLYO87ep6ef4rezZDYa_RpELa2W5Viud_JK_keq2IdyNSzZa0i2nxQ78Bvliy1KGNt_knGaCR-skPMPPgf1Z1Qbbepl1ALdfXVgSfi4gyh0MJXnTeTLJqWqp7e58h3aMADmLj7O-hXw7DYWxIPWFRDYacg3RbGXfQ6Kb6ZOqDU69ur6BDGIf7XsmdiwOZHX65V3_5w0i0Hg0HEXhiGOLle1LRBuiEWyxXb-HYfVJlgFpOXbbNxJ7XkDX-rzeW0HTACXo1xdpd64wSIbKLJ1HuPrNkuTmbuufF8SByx3LNDuEHekZQ_Wj_1Ci8nOa8Kl0FKrhd2gCwsOKCOWjUNHw95OzH3lwuzDGJ0Dnxf9RIWfpsBpbpCbLBOJMQgcv3nXGwF47ki63cI6Vpngh_00h4O_GehLA8Vnepfc8S8WeuTgd4-MVHOf3DrzMRkPyBxR-PvHz6v4o62mDn_U4I9u44_WDfX4owZ_1OGPDvGHQyrq8Uc9_h6S6euT6avTwNfwCKTgSQBlbjIu8rRKY1kpUBrf1xDpUnDQAnhc6RAgCaso4ppLncQcQig14zLDswL4I7LXtI16TGgGWaYgV5AwHQsQYF76KtExMHzCCPWEjLuNKr66TC3FXwW0f90BT8ntDUafkb3lYqWeo0q6LF9YGf8BVwqaGw |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=679%E2%80%83Pharmacokinetics+of+direct+oral+anticoagulants+in+patient+with+atrial+fibrillation+and+extreme+obesity&rft.jtitle=European+heart+journal+supplements&rft.au=Giannetti%2C+Laura&rft.au=Pezzullo%2C+Enrica&rft.au=D%E2%80%99Aquino%2C+Marco+Malvezzi+Caracciolo&rft.au=Scognamiglio%2C+Gabriella&rft.date=2021-12-08&rft.issn=1520-765X&rft.eissn=1554-2815&rft.volume=23&rft.issue=Supplement_G&rft_id=info:doi/10.1093%2Feurheartj%2Fsuab127.025&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_eurheartj_suab127_025 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1520-765X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1520-765X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1520-765X&client=summon |